Cochlear Receives FDA Approval for MP3000 Sound Strategy

MP3000, a new sound strategy from Cochlear, has received FDA approval.  The strategy promises to extend battery life about 24% over the existing SPEAK/ACE strategies.

While SPEAK/ACE are based on 8-10 spectral components, MP3000 uses 4-6 components. No significant difference was found for the speech scores and for coding preference between the SPEAK/ACE and MP3000 strategies.

Thanks as always to Bob MacPherson for breaking the news of FDA approval of the MP3000 sound processing strategy!